CX-1739

CX-1739 is a low-impact ampakine, meaning it preferentially slows AMPA-receptor deactivation while producing comparatively little effect on desensitization, which gives it a wider margin between efficacy and overexcitation than first-generation compounds ^[1]. Preclinical work confirmed that it activates AMPA receptors without causing excito-neurotoxicity and that it crosses the blood-brain barrier very rapidly, with brain penetration on the order of a couple of minutes ^[1].

The compound's most distinctive application is in respiratory pharmacology. Because the brainstem respiratory rhythm generators depend on AMPA-mediated glutamatergic drive, ampakines can counteract drug-induced respiratory depression. High-dose intravenous CX-1739 reversed respiratory depression produced by an opioid agonist, pentobarbital, and ethanol in animal models, offering a mechanism that restores breathing without antagonizing opioid analgesia the way naloxone does ^[1]. Related studies with the closely allied ampakines CX-717 and CX-1739 showed that low-dose ampakine pretreatment paired with a single brief hypoxic episode can evoke lasting phrenic motor facilitation, pointing to a role in respiratory neuroplasticity ^[3].

CX-1739 also improves behavior in cognitive and neurodevelopmental models. In the BTBR mouse model of autism, CX-1739 and the related CX-1837 reversed deficits in sociability without inducing hyperactivity or sedation ^[2]. RespireRx advanced CX-1739 into early human study for respiratory indications, making it one of the few ampakines to reach the clinic, although it has not been approved.

As a low-impact ampakine, CX-1739 was engineered specifically to avoid the excitotoxicity liability of earlier compounds, and preclinical work reported safe AMPA activation without neurotoxic signs. Early human respiratory studies were undertaken, but comprehensive tolerability data are limited and it remains investigational. General theoretical concerns for the class include headache, agitation, and overexcitation at high exposure. It is not an approved medicine and should be considered experimental.

CX-1739 was developed by Cortex Pharmaceuticals and its successor RespireRx as part of a strategy to reposition ampakines toward respiratory disorders, including opioid-induced respiratory depression and sleep apnea, where enhancing brainstem glutamatergic drive is therapeutically attractive. It advanced through preclinical characterization and into early clinical evaluation during the 2010s, and it has been studied in academic laboratories for respiratory neuroplasticity and neurodevelopmental models.

CX-1739 is regarded as one of the more clinically advanced and mechanistically attractive ampakines, particularly for its respiratory application, which distinguishes it from purely cognition-focused compounds. In the nootropic community it is discussed as a low-impact, safer-profile ampakine, though it is not readily available. Its scientific reputation rests on the novel idea of restoring breathing without reversing analgesia.